Clinical trial
A Phase 3 Multicenter, Open-label, Single-arm Trial Evaluating Home Self-Administration of Subcutaneous Maridebart Cafraglutide Via Autoinjector in Adult Participants Living With Obesity or Overweight Without Type 2 Diabetes Mellitus
NCT07871409 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Multicenter, Open-label, Single-arm Trial Evaluating Home Self-Administration of Subcutaneous Maridebart Cafraglutide Via Autoinjector in Adult Participants Living With Obesity or Overweight Without Type 2 Diabetes Mellitus
- Lead sponsor
- Amgen
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- October 28, 2026
- Completion date
- September 8, 2027
- Enrollment
- 230 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.